NewsBite

ResMed

Advertisement
The typical pay packet for a CEO of an ASX100 company was $3.87 million in the 2023 financial year, ACSI said.

ResMed, News Corp bosses top CEO pay tables in 2023

The average realised pay for the chief executive of an ASX100 company in the 2023 financial year was 50 times what an average Australian worker earned.

  • Clancy Yeates

Latest

ResMed CEO Mick Farrell.

Another biotech boom? These Aussie giants are spending up big

Sleep treatments giant ResMed has been splashing cash on projects for growth as the sector spends up to secure post-pandemic growth.

  • Emma Koehn
ResMed has benefitted from a Philips recall which affected more than 3 million devices.

Why this Aussie powerhouse is not worried about a global economic slowdown

The sleep treatments maker hopes to make its way through a global economic slowdown unscathed despite many of the markets it sells into facing serious headwinds.

  • Emma Koehn
The pandemic changed the way many of us sleep and dream.

ResMed eyes insomnia treatments after weathering chip shortage

The Australian sleep apnoea treatments maker has made two recent acquisitions focused on digital health.

  • Emma Koehn

This Aussie giant delivered life-saving tech during COVID, but can it keep soaring?

Ventilator and sleep products maker ResMed has been on a rollercoaster for two years. Are its shares a good buy after their recent price falls?

  • Emma Koehn
ResMed has benefitted from a Philips recall which affected more than 3 million devices.

Chip shortage curbs ResMed’s growth in face of surging demand

The medtech giant was forced to shave $US100 million off its revenue forecasts for capitalising on a competitor’s recall, with the stock falling 5 per cent.

  • Emma Koehn
Advertisement
ResMed is seeing incredibly strong demand for its products but cannot keep up because of

‘Very, very challenging’: Costs hit ResMed as demand soars

Sleep treatment giant ResMed says rising freight costs and semiconductor chip shortages are curbing its ability to meet surging global demand for its devices.

  • Emma Koehn
Pro Medicus chief executive Dr Sam Hupert in Melbourne this week.

The billionaire who won’t bid for Australian government health work

No debt and a focus on innovation has allowed software medical imaging company, Pro Medicus, to expand globally, turning its founders into billionaires.

  • Emma Koehn
ResMed CEO Mick Farrell says the global supply chain environment “remains very challenging”.

ResMed ready to capitalise on ‘foot fault’ by rival Philips

Supply chain issues are lingering but ResMed boss Mick Farrell says the sleep treatment maker can secure long-term market share after a competitor’s major recall.

  • Emma Koehn
ResMed could benefit from a product recall by its main competitor.

NYU accuses Resmed of patent breach over popular sleep apnoea product

New York University alleges Resmed has illegally used the university’s science to create the AirSense10 machine, one of its best-selling products.

  • Sarah Danckert

Original URL: https://www.watoday.com.au/topic/rmd-1b8